About Us

Business Development

Micro Labs is committed to opportunities and partnerships that drive growth and value

Ranked among the top 19 pharmaceutical companies in India, Micro Labs has presence in over 40 countries with ground level operations in 15 countries, exporting formulations in every therapeutic segment.

Our global presence is supported by 14 world class manufacturing facilities approved by USFDA,UK-MHRA,Health Canada, WHO,TGA Australia, MCC-South Africa & Medsafe New Zealand and 3 R & D centres in Bangalore and Mumbai with over 250 experienced scientists.

Our global growth strategy is focused on the key principles of internal product development; strategic alliances; and select mergers/acquisitions of products, technologies and companies.

As we expand our global pharmaceuticals business, Micro Labs is committed to identifying opportunities that fit our capabilities, enhance our corporate goals and strengthen our competitive position.

Micro Labs is uniquely placed in our industry -We are recognised as one of the leaders in healthcare and as a pioneer in seeking cutting edge technologies and world-class quality. We are a fully integrated pharmaceutical business capable of developing, manufacturing, marketing and distributing products on its own, we also recognize the value of collaboration.

By leveraging our combined assets, expertise and capabilities, we can lower costs, increase productivity and, ultimately, produce a medicine that helps patients.

Micro Labs takes a strategic approach to business development activities, ensuring that the expectations of our partners are aligned with our own. Micro Labs offers its partners strong R & D and commercial resources as well as the experience needed to guide products through the regulatory process.

However, building a next generation pharmaceutical company requires new technologies, new ideas, new products and new insights. These can be found anywhere and everywhere in the world.

If you have innovations or ideas that will help transform our industry we want to hear from you. We invite academic institutions and pharmaceutical or biotech companies that share our goal of helping to address unmet medical needs to contact us with proposals.

ADVICE ABOUT REPORTING

  • Report adverse experiences with medications
  • Report serious adverse reactions. A reaction is serious when the patient outcome is:
    • Death
    • Life-threatening (real risk of dying)
    • Hospitalization (initial or prolonged)
    • Disability (significant, persistent or permanent)
    • Congenital anomaly
    • Required intervention to prevent permanent impairment or damage
  • Report even if:
    • You’re not certain the product caused adverse reaction
    • You don’t have all the details however point nos. 1, 5, 7, 8, 11, 15, 16 & 18 (see reverse) are essentially required.
  • Who can report:
    • Any health care professional (Doctors including Dentists, Nurses and Pharmacists).
  • Where to report:
    • After completing, please return this form to Micro Labs Ltd, Pharmacovigilance Cell
  • What happens to the submitted information:
    • Information provided in this form is handled in strict confidence. PV cell at Micro Labs will carry out causality analysis and the data is statistically analysed and finally submitted to CDSCO.

Confidentiality:

The patient’s identity is held in strict confidence and protected to the fullest extent. Programme staff is not expected to and will not disclose the reporter’s identity in response to a request from the public. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction.